Lung Cancer Surgery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Type (Thoracotomy (Lobectomy, Sleeve Resection, Segmentectomy, Pneumonectomy), Minimally Invasive Surgeries), By End User (Hospitals, Ambulatory Surgical Centers, Others), By Region & Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 5.67 Billion

Market Size (2029)

USD 7.26 Billion

CAGR (2024-2029)

4.21%

Fastest Growing Segment

Segmentectomy

Largest Market

North America

Market Overview

Global Lung Cancer Surgery Market was valued at USD 5.67 billion in 2023 and is expected to reach USD 7.26 billion by 2029 with a CAGR of 4.21% during the forecast period. The lung cancer surgery market is growing due to advances in surgical techniques and increasing incidence of lung cancer. Innovations such as minimally invasive procedures and robotic-assisted surgeries are enhancing patient outcomes and expanding treatment options. The market is driven by rising awareness, early detection, and improved healthcare infrastructure supporting complex surgeries.

Key Market Drivers

Growing Technological Advancement

Technological innovations play a pivotal role in driving growth within the lung surgery market. Advancements in surgical techniques, imaging modalities, and robotic-assisted surgery have significantly improved outcomes for patients undergoing lung surgeries. Minimally Invasive Surgery (MIS), including video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery (RATS), has revolutionized the field by reducing post-operative pain, shortening hospital stays, and accelerating recovery compared to traditional open surgeries. Robotic platforms such as the da Vinci Surgical System enable surgeons to execute intricate lung resections with unparalleled precision and minimal invasiveness, appealing to both medical professionals and patients due to benefits like enhanced visualization, smaller incisions, and reduced surgical trauma. Advanced imaging technologies like high-resolution CT, MRI, and PET scans play pivotal roles in preoperative planning and intraoperative guidance, facilitating accurate tumor localization, assessment of surgical margins, and detection of metastases, thereby enhancing overall surgical outcomes. Complementing these advancements are image-guided navigation systems that assist in pinpointing pulmonary lesions during VATS procedures, utilizing sophisticated tracking technologies to provide real-time feedback and enhance surgical accuracy while minimizing invasiveness.

Additionally, the integration of advanced energy devices such as electrosurgical instruments, harmonic scalpels, and lasers ensures precise tissue dissection, effective hemostasis, and reduced intraoperative blood loss, contributing to shorter operating times and improved surgical efficiency. Together, these technological innovations underscore a transformative era in lung surgery, characterized by enhanced precision, reduced patient morbidity, and improved overall clinical outcomes.

Demographic Trends and Growing Disease Burden

The influence of demographic factors and the epidemiology of lung diseases significantly influence the demand for lung surgeries. The global aging population is increasingly vulnerable to lung diseases such as lung cancer, COPD, and pneumonia, driving up the demand for surgical interventions as elderly individuals comprise a larger proportion of patients requiring treatment. Concurrently, the prevalence of lung cancer continues to rise globally, fueled by risk factors like smoking, environmental pollution, and occupational exposures, necessitating surgical management for a substantial number of cases. COPD, a prevalent chronic respiratory condition characterized by airflow limitation, predominantly affects the elderly population, often necessitating surgical options like lung volume reduction surgery (LVRS) or lung transplantation in severe cases where medical therapies are insufficient. As per World Health Organization and Globocan, a total of 36,871 individuals were identified to have lung cancer in Germany which is nearly 6% of the total 605,805 cancer cases in 2020. Lung cancer was ranked 2nd based on its incidence rates while it was considered the top reason behind the deaths caused by cancer. Moreover, urbanization and industrialization contribute to higher levels of air pollution and occupational hazards, exacerbating respiratory diseases and further boosting the demand for lung surgeries, particularly in densely populated urban regions where environmental factors play a significant role in disease incidence. These demographic and environmental factors collectively underscore the increasing importance of lung surgeries in addressing the growing burden of respiratory diseases globally.

Growing Demand for Personalized Medicine

The Change in patient preferences and the demand for personalized medicine are reshaping the landscape of lung surgery, driving innovation and adoption of tailored treatment approaches. Increasingly, patients prioritize outcomes that prioritize quicker recovery times, reduced pain, and improved cosmetic results, leading to a preference for minimally invasive and robotic-assisted surgeries. These techniques not only align with patient desires for less traumatic procedures but also offer benefits such as enhanced precision and minimized recovery times, enhancing overall patient satisfaction. Moreover, advances in precision medicine have revolutionized lung cancer treatment by leveraging molecular diagnostics and genomic profiling. These technologies enable healthcare providers to personalize treatment strategies based on the unique molecular characteristics of each patient's tumor. Targeted therapies and immunotherapies tailored to specific genetic mutations or biomarkers influence surgical decision-making and post-operative management, improving treatment efficacy and patient outcomes.

Furthermore, the shift towards multidisciplinary care models is increasingly prevalent in lung cancer treatment. Collaborative teams comprising surgeons, medical oncologists, radiation oncologists, pulmonologists, and other specialists collaborate to develop comprehensive and individualized treatment plans. This integrated approach ensures that patients receive holistic care that addresses all aspects of their condition, from diagnosis through to recovery. Multidisciplinary care models not only enhance treatment outcomes but also optimize patient satisfaction by providing coordinated and cohesive care pathways. 

Download Free Sample Report

Key Market Challenges

Advanced Stage Diagnosis Among Patients

The lung cancer surgery market faces significant challenges that impact the effectiveness of treatment and patient outcomes. One primary challenge is the prevalence of advanced-stage diagnoses among patients. A substantial number of lung cancer cases are detected at later stages, limiting the feasibility of curative surgical interventions. Late-stage diagnosis not only reduces the likelihood of successful surgical outcomes but also complicates treatment planning by necessitating more aggressive therapies and multidisciplinary approaches. Efforts to improve early detection through enhanced screening programs and public awareness campaigns are crucial in addressing this challenge and potentially increasing the proportion of patients eligible for surgical interventions at earlier, more treatable stages.

Surging Cost and Reimbursement Issues

Another critical challenge in the lung cancer surgery market relates to the cost and reimbursement landscape. The high costs associated with lung cancer surgeries, including diagnostic imaging, surgical procedures, and post-operative care, present financial barriers for patients and healthcare systems alike. Inadequate reimbursement for advanced surgical techniques and personalized treatments further exacerbates these challenges, impacting access to optimal care and treatment outcomes. Addressing these cost-related issues requires collaborative efforts among healthcare providers, policymakers, and insurers to develop sustainable reimbursement strategies that support innovation while ensuring equitable access to high-quality surgical care for all patients with lung cancer.

Key Market Trends

Advancement in Minimally Invasive and Robotic-Assisted Surgery

One of the prominent trends in the lung cancer surgery market is the increasing adoption of minimally invasive techniques and robotic-assisted surgery. Minimally invasive approaches, such as video-assisted thoracoscopic surgery (VATS), have gained popularity due to their ability to minimize surgical trauma, reduce post-operative pain, shorten hospital stays, and accelerate recovery compared to traditional open surgeries. VATS allows surgeons to perform lung resections through small incisions, using a video camera and specialized instruments for precision and visualization.

Robotic-assisted surgery, exemplified by systems like the da Vinci Surgical System, has further revolutionized lung cancer surgery by enhancing surgical precision and dexterity. Robotic platforms enable surgeons to operate with enhanced 3D visualization and articulating instruments, facilitating complex procedures with greater accuracy and control. This technology is particularly beneficial for intricate surgeries, such as pulmonary lobectomy or mediastinal lymph node dissection, offering advantages like reduced blood loss, fewer complications, and faster recovery times.

The adoption of minimally invasive and robotic-assisted techniques continues to grow as healthcare providers prioritize approaches that optimize patient outcomes while minimizing procedural risks and recovery times. Ongoing advancements in robotic technology, including improvements in ergonomics, instrument design, and integration with imaging modalities, are expected to further enhance the capabilities and accessibility of robotic-assisted lung surgeries.

Growing Personalized Medicine and Targeted Therapies

The growing trend for integration of personalized medicine and targeted therapies into treatment paradigms. Precision medicine approaches leverage molecular diagnostics, genomic profiling, and biomarker testing to tailor treatment strategies based on the unique genetic and molecular characteristics of each patient's tumor. Advances in molecular diagnostics enable oncologists to identify specific genetic mutations, such as EGFR, ALK, ROS1, and BRAF alterations, which guide the selection of targeted therapies. Targeted therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, inhibit specific molecular pathways involved in cancer growth and progression, offering improved efficacy and reduced toxicity compared to traditional chemotherapy.

Furthermore, immunotherapy has emerged as a promising treatment modality for lung cancer, particularly in patients with advanced or metastatic disease. Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, enhance the body's immune response against cancer cells by blocking inhibitory signals that suppress immune function. Immunotherapy is increasingly integrated into multidisciplinary treatment regimens for lung cancer, either as monotherapy or in combination with surgery, chemotherapy, or radiation therapy.

The rise of personalized medicine and targeted therapies underscores a paradigm shift towards individualized treatment approaches in lung cancer surgery. Molecular profiling and biomarker testing are becoming standard practice to guide treatment decisions, optimize therapeutic outcomes, and minimize adverse effects for patients. As research continues to uncover new biomarkers and therapeutic targets, the landscape of lung cancer surgery is expected to further evolve, offering new avenues for improving patient survival and quality of life.

Segmental Insights

Type Insights

Based on the type, the segmentectomy category is projected to experience rapid growth during the forecast period. With the increasing prevalence of lung cancer and advancements in technology, early-stage treatment options have expanded, contributing to the anticipated growth of the lung cancer surgery market. Segmentectomy, a common surgical approach for treating non-small cell lung cancer (NSCLC), is often preferred over lobectomy when patients have limited lung function. While segmentectomy has traditionally been used for benign masses and early-stage cancers, its popularity has grown due to superior outcomes, reduced post-operative pain, and quicker recovery compared to conventional surgical methods. The procedure boasts high success rates in removing localized tumors and maintaining organ function to a significant extent, which is expected to drive market expansion. However, segmentectomy does carry risks associated with general anesthesia, including increased bleeding, blood clots, pneumonia, and surgical site infections.




Download Free Sample Report

Regional Insights

North America emerged as the dominant player in the global lung cancer surgery market in 2022, holding the largest market share in terms of both value and volume. The large portion of North America can be attributed to the rising prevalence of lung cancer, rising incidence and prevalence of lung cancer, rising tobacco use, growing emphasis on early cancer diagnosis and treatment, and the accessibility of reimbursement. According to estimates from the American Cancer Society in 2024, there were approximately 234,580 new cases of lung cancer in the United States, with an expected 125,070 deaths attributed to the disease. Over recent years, improvements in lung cancer survival rates have been observed alongside an increase in the diagnosis of localized lung cancer cases. The American Lung Association reported in 2023 that the survival rate has increased by 22% nationally to 26.6%, over the past five years. Additionally, it has increased at a faster pace among communities of color such that it is no longer significantly lower compared to white Americans. Moreover, each year, tens of thousands of individuals in the U.S. achieve remission from non-small cell lung cancer (NSCLC). Given that lung cancer predominantly affects older adults, these statistics underscore the significant burden of the disease in the U.S. healthcare system, driving demand for cancer treatment and contributing to the growth of the market studied.

Recent Developments

  • In May 2024 - Novant Health has recently introduced advanced robotics to enhance the diagnosis and treatment of lung cancer. This cutting-edge technology aims to improve precision and outcomes in lung cancer surgeries by providing surgeons with greater control and accuracy.
  • In March 2024 - bioAffinity Technologies, Inc. reported accelerating growth of 375% in CyPath® Lung tests ordered and processed over the past three months as compared to the previous three months. CyPath® Lung is a noninvasive test to detect early-stage lung cancer.
  • In February 2024 - Philips has unveiled LumiGuide, a revolutionary imaging technology that uses light for navigation instead of X-rays, marking a significant advancement in minimally invasive surgery. Utilizing Fiber Optic RealShape (FORS) technology, LumiGuide allows precise navigation through blood vessels, reducing radiation exposure.
  • In October 2023 - American College of Emergency Physicians Scientific Assembly (ACEP23) in Philadelphia, Philips showcased its latest innovations in point-of-care ultrasound (POCUS). Highlighting the Ultrasound Compact System 5000 Series, Lumify Handheld Ultrasound, and Philips Collaboration Live tele-ultrasound, Philips emphasized the integration of AI to enhance diagnostic accuracy and patient care in emergency settings.

Key Market Players

  • Accuray Inc.
  • AngioDynamics Inc.
  • Johnson & Johnson Services, Inc.
  • Intuitive Surgical Inc.
  • Olympus Corporation
  • Teleflex Incorporated
  • Ackermann Instrumente GmbH
  • KARL STORZ GmbH
  • Medtronic Plc.
  • Siemens Healthineers AG

 By Type

By End Use

By Region
  • Thoracotomy
  • Minimally Invasive Surgeries

 
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Lung Cancer Surgery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Lung Cancer Surgery Market, By Type:

o   Thoracotomy

§  Lobectomy

§  Sleeve Resection

§  Segmentectomy

§  Pneumonectomy

o   Minimally Invasive Surgeries

  • Lung Cancer Surgery Market, By End Use:

o   Hospitals

o   Ambulatory Surgical Centers

o   Others

  • Lung Cancer Surgery Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Egypt

§  Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Surgery Market.

Available Customizations:

Global Lung Cancer Surgery market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Lung Cancer Surgery Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, and Trends

4.    Voice of Customer

5.    Global Lung Cancer Surgery Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Type (Thoracotomy (Lobectomy, Sleeve Resection, Segmentectomy, Pneumonectomy), Minimally Invasive Surgeries)

5.2.2.     By End Use (Hospitals, Ambulatory Surgical Centers, Others)

5.2.3.     By Company (2023)

5.2.4.     By Region

5.3.  Market Map

6.    North America Lung Cancer Surgery Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type

6.2.2.     By End Use

6.2.3.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Lung Cancer Surgery Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Type

6.3.1.2.2.             By End Use

6.3.2.     Mexico Lung Cancer Surgery Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Type

6.3.2.2.2.             By End Use

6.3.3.     Canada Lung Cancer Surgery Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Type

6.3.3.2.2.             By End Use

7.    Europe Lung Cancer Surgery Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type

7.2.2.     By End Use

7.2.3.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Lung Cancer Surgery Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type

7.3.1.2.2.             By End Use

7.3.2.     Germany Lung Cancer Surgery Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type

7.3.2.2.2.             By End Use

7.3.3.     United Kingdom Lung Cancer Surgery Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type

7.3.3.2.2.             By End Use

7.3.4.     Italy Lung Cancer Surgery Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Type

7.3.4.2.2.             By End Use

7.3.5.     Spain Lung Cancer Surgery Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Type

7.3.5.2.2.             By End Use

8.    Asia-Pacific Lung Cancer Surgery Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type

8.2.2.     By End Use

8.2.3.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Lung Cancer Surgery Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type

8.3.1.2.2.             By End Use

8.3.2.     India Lung Cancer Surgery Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type

8.3.2.2.2.             By End Use

8.3.3.     South Korea Lung Cancer Surgery Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type

8.3.3.2.2.             By End Use

8.3.4.     Japan Lung Cancer Surgery Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Type

8.3.4.2.2.             By End Use

8.3.5.     Australia Lung Cancer Surgery Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Type

8.3.5.2.2.             By End Use

9.    South America Lung Cancer Surgery Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.2.     By End Use

9.2.3.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Lung Cancer Surgery Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.2.             By End Use

9.3.2.     Argentina Lung Cancer Surgery Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.2.             By End Use

9.3.3.     Colombia Lung Cancer Surgery Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.2.             By End Use

10.  Middle East and Africa Lung Cancer Surgery Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type

10.2.2.  By End Use

10.2.3.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Lung Cancer Surgery Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type

10.3.1.2.2.           By End Use

10.3.2.  Saudi Arabia Lung Cancer Surgery Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type

10.3.2.2.2.           By End Use

10.3.3.  UAE Lung Cancer Surgery Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type

10.3.3.2.2.           By End Use

10.3.4.  Egypt Lung Cancer Surgery Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Type

10.3.4.2.2.           By End Use

10.3.5.  Turkey Lung Cancer Surgery Market Outlook

10.3.5.1.      Market Size & Forecast

10.3.5.1.1.           By Value

10.3.5.2.      Market Share & Forecast

10.3.5.2.1.           By Type

10.3.5.2.2.           By End Use

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Merger & Acquisition (If Any)

12.2.              Product Launches (If Any)

12.3.              Recent Developments

13.  Porters Five Forces Analysis

13.1.              Competition in the Industry

13.2.              Potential of New Entrants

13.3.              Power of Suppliers

13.4.              Power of Customers

13.5.              Threat of Substitute Products

14.  Competitive Landscape

14.1.              Accuray Inc.

14.1.1.  Business Overview

14.1.2.  Company Snapshot

14.1.3.  Products & Services

14.1.4.  Financials (As Reported)

14.1.5.  Recent Developments

14.1.6.  Key Personnel Details

14.1.7.  SWOT Analysis

14.2.              AngioDynamics Inc.

14.3.              Johnson & Johnson Services, Inc.

14.4.              Intuitive Surgical Inc.

14.5.              Olympus Corporation

14.6.              Teleflex Incorporated

14.7.              Ackermann Instrumente GmbH

14.8.              KARL STORZ GmbH

14.9.              Medtronic Plc.

14.10.            Siemens Healthineers AG

15.  Strategic Recommendations

16.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Lung Cancer Surgery Market was estimated to be USD 5.67 billion in 2023.

down-arrow

Accuray Inc., AngioDynamics Inc., Ethicon US, LLC, Intuitive Surgical Inc., Olympus Corporation, Teleflex Incorporated, Ackermann Instrumente GmbH, KARL STORZ GmbH, Medtronic Plc., Siemens Healthineers AG/The were some of the key players operating in the Global Lung Cancer Surgery Market.

down-arrow

Surging cost and reimbursement issues, advanced stage diagnosis among patients, are some of the major challenges faced by the Global Lung Cancer Surgery Market in the upcoming years.

down-arrow

Growing technological advancement, demographic trends and growing disease burden, and growing demand for personalized medicine are the major drivers for the Global Lung Cancer Surgery Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Lung Cancer Surgery Market to Grow with a CAGR of 4.21% through 2029

Nov, 2024

Increase in the incidence and prevalence of lung cancer and increase in the aging population is expected to drive the Global Lung Cancer Surgery Market growth in the forecast period, 2025-2029.

Why Choose Us